Apoptosis inducer 56
Apoptosis inducer 56 is an apoptosis inducer. Apoptosis inducer 56 induces DNA damage (upregulation of γH2AX and p-ATM expression) by minor groove binding. Apoptosis inducer 56 induces intrinsic apoptosis (upregulation of p53 and Bax/Bcl-2 ratio, cleaved caspase-7) via S-phase cell cycle arrest. Apoptosis inducer 56 shows selectivity for cancer cells over normal breast epithelial cells. Apoptosis inducer 56 can be used for the research of breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 952306-31-9
- Formula: C11H17N3O3S
- Molecular Weight:271.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Caspase-7 |
Bax |
Bcl-2 |
In Vitro
Apoptosis inducer 56 (compound 1) (5-60 μM; 24 h) selectively induces cytotoxicity in MCF-7 human breast cancer cells with an IC50 of 21.18 μM and does not exhibit notable cytotoxicity in non-malignant MCF-10A breast epithelial cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) inhibits proliferation and colony formation, and induces S-phase cell cycle arrest in MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces 45% apoptosis in MCF-7 human breast cancer cells and does not induce apoptosis in non-malignant MCF-10A breast epithelial cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces DNA damage-mediated apoptosis, and induces mitochondrial membrane depolarization in 75.8% of MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM) activates the DNA damage response (upregulates γ-H2AX, p-ATM, p-Chk2) and suppresses DNA repair (downregulates p-BRCA1) in MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces mitochondria-dependent apoptosis in MCF-7 human breast cancer cells via upregulation of pro-apoptotic proteins, cytochrome c release, caspase activation, and PARP cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 human breast cancer cells, MCF-10A non-malignant breast epithelial cells
-
Concentration:5, 10, 20, 40, 60 μM
-
Incubation Time:24 h
-
Result:Induced cytotoxicity in MCF-7 cells with an IC₅₀ of 21.18 ± 2.01 μM; maintained >70% viability in MCF-10A cells across 5, 10, 20, 40, 60 μM.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Reduced cell proliferation from 83.1% (control) to 66.3%.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Increased S-phase cell accumulation from 17.4% (control) to 30.1%.
-
Cell Line:MCF-7 human breast cancer cells, MCF-10A non-malignant breast epithelial cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Induced 45% apoptosis in MCF-7 cells compared to 2.62% in the control group; maintained 95.8% viability in MCF-10A cells after 24 h treatment.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Caused a substantial increase in TUNEL-positive cells (green fluorescence) compared to the untreated group.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Upregulated pro-apoptotic Bim and Bax; downregulated anti-apoptotic Bcl2 and Bcl-xL; elevated p53; suppressed survivin; induced cytochrome c release from mitochondria to cytoplasm; upregulated Apaf-1; activated caspase-7 and caspase-9 via cleavage; induced PARP cleavage.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (adult female, 25-28 g)[1]
-
Dosage:1, 2.5, 5, 10 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Detected no significant adverse effects on liver, renal, biochemical, or hematological parameters; observed no treatment-related behavioral deviations; maintained stable body weights across all dose groups; showed no structural abnormalities in liver and kidney tissues via histopathological analysis.
Chemical Information
-
CAS No. 952306-31-9
-
Molecular Weight 271.34
-
Formula C11H17N3O3S
-
SMILES
O=C(CCCCCCC(NO)=O)NC1=NC=CS1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)